F18 radiopharmaceuticals

The Department of Veterans Affairs, Veterans Integrated Service Network 7, is soliciting F-18 radiopharmaceutical products and delivery services for the Nuclear Medicine Service at Atlanta Veterans Affairs Healthcare System. The solicitation (36C24726R0060) seeks multiple radiopharmaceutical products including F18-FDG, F18-NaF, F18-Pylarify, CAIX targeted PET radiopharmaceuticals, choline PET radiopharmaceuticals, and F18-FET, with base year quantities ranging from 1 to 1,970 unit doses depending on the product type. Vendors must be established commercial radiopharmacies with at least ten years of continuous operation, hold current US NRC or Agreement State licensure for radiopharmaceutical preparation and distribution, possess FDA-approved cyclotrons, and maintain full compliance with federal and state radioactive materials regulations. Evaluation will be based on technical capability, past performance, and price, with technical capability and past performance weighted as more significant factors than pricing. The offer due date is April 30, 2026, at 10:00 AM EDT, and the Contracting Officer Natasha Mixon should be contacted at Natasha.Mixon@va.gov for all inquiries.

This solicitation is a 100% Service-Disabled Veteran-Owned Small Business set-aside under NAICS code 325412 with a size standard of 1,300 employees. The contract structure consists of a one-year base period running from June 20, 2026, through June 19, 2027, with four optional one-year renewal periods extending through June 19, 2031. The contractor must provide daily delivery Monday through Friday from 7:00 AM to 5:00 PM with emergency four-hour response capability during standard business hours at the Atlanta Veterans Affairs Medical Center located at 1670 Clairmont Road, Decatur, Georgia 30033. The contractor shall include all labor, supervision, and transportation in the firm-fixed-price bid without explicit delivery charges or fuel surcharges, with monthly invoicing and payment via electronic funds transfer. Specific contract values are not disclosed in the solicitation documents, though the estimated annual quantities and multi-year option periods indicate a substantial procurement for radiopharmaceutical services.